(100 days)
Not Found
No
The description focuses on the electrothermal mechanism of action and does not mention any AI/ML components or functionalities.
Yes
The CELFIRM™ is explicitly intended for use in "dermatologic and general surgical procedures for electrocoagulation and hemostasis," which are therapeutic interventions. The device description further details its mechanism for "coagulating the tissue" by generating heat, confirming its therapeutic action.
No
The device is intended for electrocoagulation and hemostasis, which are treatment procedures, not diagnostic ones. It generates heat to coagulate tissue, rather than to identify or characterize a disease or condition.
No
The device description explicitly details hardware components including a system main device, hand-piece, tip, and footswitch, and describes the generation and delivery of an RF signal through these components.
Based on the provided information, the CELFIRM™ device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "electrocoagulation and hemostasis in dermatologic and general surgical procedures." This describes a therapeutic or surgical intervention performed directly on a patient's tissue, not a test performed on a sample taken from the body to diagnose a condition.
- Device Description: The description details how the device delivers RF energy to tissue via needle electrodes to cause coagulation. This is a physical interaction with the body, not an analysis of a biological sample.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (like blood, urine, tissue biopsies, etc.), detecting analytes, or providing diagnostic information based on laboratory testing.
IVD devices are specifically designed to examine specimens derived from the human body to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. The CELFIRM™ device's function is to directly modify tissue through electrocoagulation.
N/A
Intended Use / Indications for Use
The CELFIRM™ is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
Product codes
GEI
Device Description
The CELFIRM™ includes a system main device, a hand-piece equipped with a tip, and a footswitch. The RF signal is generated from the main device which is then delivered to the hand-piece and then to consumable tip. The RF signal is delivered to the target tissue using penetrating needle electrodes in the tip. The tip is placed in light contact with the epidermis while the hand-piece is being held at right angles to the target tissue. As the RF signal passes through the skin, it generates an electro thermal reaction which is capable of coagulating the tissue. Using the consumable tip, CELFIRM™ creates heat within the target skin tissue via needle electrodes from the consumable tip.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Sterilization Validation, Shelf life Validation, Biocompatibility, Software Validation, EMC & Electrical Safety Test, Max Output Energy, and Animal Test were conducted on the subject device.
- Sterilization Validation Test: To verify the sterility assurance level (106) for EtO sterilization, the validation and biological indicator (BI) overkill method was used in accordance to ISO 11135-1, ISO 10993-1, ISO 10993-7, ISO 11138-1, ISO 11138-2, ISO 11737-1, ISO 11737-2, AAMI TIR 15, and ISO 13485:2012.
- Shelf life Validation Test: The tests to validate the shelf life of the device through the proposed shelf life were conducted using the accelerated aging method in accordance to ASTM F1980-07 (2011) Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices. The referenced standards for the testing are ISO 11607-1, ISO 11607-2, ISO 11737-2, ASTM F1929, ASTM F 88, and USP-NF .
- Biocompatibility Test: The patient contacting component of the subject device is the Consumable Tip and the biocompatibility tests were in accordance with ISO 10993-4. ISO 10993-5, ISO 10993-7. ISO 10993-10, ISO 10993-11, and USP 39.
- Software Validation Test: The level of concern of the software (firmware) of the CELFIRM™ is moderate and the software validation tests were performed.
- EMC & Electrical Safety Test: The CELFIRM™ has been evaluated for electromagnetic compatibility and electrical safety testing per applicable standards of IEC 60601-1:2005. IEC 6061-1-6:2010. IEC 60601-2-2:2009. EN 60601-1-2:2007, EN 6100-3-2:2006, and EN 6100-3-3:2008, and all the tests met the pre-set criteria.
- Max Output Energy: The test on Max Output Energy per Electrode was performed on the subject device to evaluate the max energy per electrode. The test results were compared and evaluated with the standard values of maximum output energy per Electrode of CELFIRM™. The test results met the pre-set criteria and validated the device performance specifications for max energy.
- Preclinical Test: This study was designed to evaluate the safety and effectiveness of CELFIRM™ using Yucatan Mini-pigs. Animal were euthanized 3 h after application on Day 1, Day 4, and Day 22. Application with the CELFIRM™ device resulted in transient very slight to well-defined erythema noted within 3-4 h of application but fully resolved by the next Draize evaluation on Day 3. In addition, minimal to mild necrosis was noted in animals euthanized on Days 1 and 5 with the animal euthanized on Day 22 showing dermal fibrosis at the applied sites. There were no other application-related findings.
Test results including histology data demonstrated that the subject device is substantially equivalent to the predicate devices in the market for its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
October 13, 2017 VIOL Co., Ltd. % Priscilla Chung Regulatory Affairs Specialist LK Consulting Group USA, Inc. 690 Roosevelt. Irvine, California 92620
Re: K172023
Trade/Device Name: CELFIRM Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical Cutting and Coagulation Device and Accessories Regulatory Class: Class II Product Code: GEI Dated: June 29, 2017 Received: July 5, 2017
Dear Priscilla Chung:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820):
1
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely, Jennifer R. Stevenson -S For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices
Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K172023
Device Name
CELFIRM™
Indications for Use (Describe)
The CELFIRM™ is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
(K172023)
This summary of 510(k) is being submitted in accordance with requirements of 21 CFR Part 807.92.
Date: October 12, 2017
1. 510K Applicant / Submitter:
VIOL Co., Ltd. C-808, 809, Bundang Technopark C, 744, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do (13510), South Korea
Phone : +82-31-8017-7893 Fax : +82-31-8016-7894
2. Submission Contact Person
LK Consulting Group USA, Inc. 690 Roosevelt, Irvine CA 92620 Priscilla Juhee Chung Phone: 714.202.5789 Fax: 714-409-3357 Email: juhee.c@lkconsultinggroup.com
3. Device
- Proprietary Name: CELFIRM™ .
- Common Name: Radiofrequency System ●
- Classification: 21 CFR 878.4400 .
Electrosurgical, Cutting & Coagulation & Accessories
- Product Code: GEI
4. Predicate Device
INFINI Radiofrequency System by Lutronic Corporation (K121481)
4
5. Description:
The CELFIRM™ includes a system main device, a hand-piece equipped with a tip, and a footswitch. The RF signal is generated from the main device which is then delivered to the hand-piece and then to consumable tip. The RF signal is delivered to the target tissue using penetrating needle electrodes in the tip. The tip is placed in light contact with the epidermis while the hand-piece is being held at right angles to the target tissue. As the RF signal passes through the skin, it generates an electro thermal reaction which is capable of coagulating the tissue. Using the consumable tip, CELFIRM™ creates heat within the target skin tissue via needle electrodes from the consumable tip.
6. Indications for Use
The CELFIRM™ is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
7. Substantial Equivalence Discussion:
| Proposed Device | Predicate Device | |
|---|---|---|
| Manufacturer | VIOL Co., Ltd. | Lutronic Corporation |
| Device Name | CELFIRM™ | INFINI Radiofrequency System |
| 510(K) No. | K172023 | K121481 |
| Indications for Use | The CELFIRMTM is intended for use in | |
| dermatologic and general surgical | ||
| procedures for electrocoagulation and | ||
| hemostasis. | The INFINI Radiofrequency System is | |
| intended for use in dermatologic and | ||
| general surgical procedures for | ||
| electrocoagulation and hemostasis, and | ||
| the percutaneous treatment of facial | ||
| wrinkles. | ||
| Electrical Safety/EMC | IEC 60601-1:2005, | |
| IEC 6061-1-6:2010, | ||
| IEC 60601-2-2:2009, | ||
| EN 60601-1-2:2007, | ||
| EN 6100-3-2:2006 | ||
| EN 6100-3-3:2008 | IEC 60601-1, | |
| IEC 60601-2-2, | ||
| IEC 60601-1-2 | ||
| Input Voltage | AC100-240V, 50/60 Hz | AC100-240V, 50/60 Hz |
| Operation Type | Coagulation | Coagulation |
| Foot Switch | Yes | Yes |
| Tip Sterilization Method | EO Gas | EO Gas |
| Number of Usage | Single use | Single use |
| Dimensions | 550 mm(W) x 350 mm(L) x 1220 mm(H) | 362 mm(W) x 409 mm(L) x 1713 mm(H) |
The CELFIRM™ has similar intended uses and technical characteristics to the INFINI Radiofrequency System made by Lutronic Corporation. The similarities and differences between the systems are described in the table shown above. In summary, CELFIRM™ does not induce any new potential safety risks nor efficacy. We conclude that the CELFIRM™ is substantially equivalent to the predicate device.
5
8. Performance Tests (Non-clinical)
Sterilization Validation, Shelf life Validation, Biocompatibility, Software Validation, EMC & Electrical Safety Test, Max Output Energy, and Animal Test were conducted on the subject device.
Sterilization Validation Test
To verify the sterility assurance level (106) for EtO sterilization, the validation and biological indicator (BI) overkill method was used in accordance to ISO 11135-1, ISO 10993-1, ISO 10993-7, ISO 11138-1, ISO 11138-2, ISO 11737-1, ISO 11737-2, AAMI TIR 15, and ISO 13485:2012.
Shelf life Validation Test
The tests to validate the shelf life of the device through the proposed shelf life were conducted using the accelerated aging method in accordance to ASTM F1980-07 (2011) Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices. The referenced standards for the testing are ISO 11607-1, ISO 11607-2, ISO 11737-2, ASTM F1929, ASTM F 88, and USP-NF .
Biocompatibility Test
The patient contacting component of the subject device is the Consumable Tip and the biocompatibility tests were in accordance with ISO 10993-4. ISO 10993-5, ISO 10993-7. ISO 10993-10, ISO 10993-11, and USP 39.
Software Validation Test
The level of concern of the software (firmware) of the CELFIRM™ is moderate and the software validation tests were performed.
EMC & Electrical Safety Test
The CELFIRM™ has been evaluated for electromagnetic compatibility and electrical safety testing per applicable standards of IEC 60601-1:2005. IEC 6061-1-6:2010. IEC 60601-2-2:2009. EN 60601-1-2:2007, EN 6100-3-2:2006, and EN 6100-3-3:2008, and all the tests met the pre-set criteria.
Max Output Energy
The test on Max Output Energy per Electrode was performed on the subject device to evaluate the max energy per electrode. The test results were compared and evaluated with the standard values of maximum output energy per Electrode of CELFIRM™. The test results met the pre-set criteria and validated the device performance specifications for max energy.
Preclinical Test
This study was designed to evaluate the safety and effectiveness of CELFIRM™ using Yucatan Mini-pigs. Animal were euthanized 3 h after application on Day 1, Day 4, and Day 22. Application with the CELFIRM™ device resulted in transient very slight to well-defined erythema noted within 3-4 h of application but fully resolved by the next Draize evaluation on Day 3. In addition, minimal to mild necrosis was noted in animals euthanized on Days 1 and 5
6
with the animal euthanized on Day 22 showing dermal fibrosis at the applied sites. There were no other application-related findings.
Test results including histology data demonstrated that the subject device is substantially equivalent to the predicate devices in the market for its intended use.
9. Conclusions:
Based on the test results provided in this submission including Sterilization Validation, Shelf life Validation, Biocompatibility, Software Validation, EMC & Electrical Safety Test, Max Output Energy, and Animal Test, VIOL Co., Ltd. concludes that the CELFIRM™ is substantially equivalent to the predicate device as described herein in.